Precio Argent BioPharma Limited (RGTLF)

Argent BioPharma Ltd. engages in the production of medical marijuana. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. The Company’s assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The Company’s proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection. The company focuses on urgent unmet needs in the central nervous system (CNS) and systemic inflammation. Its product pipeline includes CimetrA, CannEpil, CogniCann and others. CannEpil is a refractory epilepsy seizure control treatment. CogniCann is an investigational oral spray developed by the Company to help manage symptoms associated with dementia and Alzheimer’s disease. The firm has a patient base in Australia, the United Kingdom, Brazil, and Ireland.